Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.58 |
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549500 | 1.00 | MAOA (0.58) | MAOAMAOBNPC1RAB9ATDP1 | |
| 3-Hydroxybenzaldehyde SCHEMBL6558945 | 0.92 | MAOA (0.55) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL2559958 | 0.85 | MAOA (0.62) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL8776563 | 0.85 | NPC1 (0.47) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL6507944 | 0.83 | MAOA (0.49) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL15823982 | 0.83 | MAOA (0.55) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL1520719 | 0.82 | MEN1 (0.50) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4198376 | 0.82 | ALDH1A1 (0.45) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL19633099 | 0.82 | KDM4E (0.49) | MAOAMAOBNPC1RAB9ATDP1 | |
| SCHEMBL22322063 | 0.81 | MAOA (0.62) | MAOAMAOBNPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014203278-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID | MSN LABORATORIES PRIVATE LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| US-20250282795-A1 | EGFR Inhibitors in cancer treatment | CELYN THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4511376-A2 | EGFR INHIBITORS IN CANCER TREATMENT | Celyn Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| CN-114436978-B | Antifungal compound and application thereof | 中国人民解放军海军军医大学 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023205595-A2 | EGFR INHIBITORS IN CANCER TREATMENT | CELYN THERAPEUTICS, INC (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-4095134-A1 | POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL INDICATIONS | UCL Business Ltd (GB) | 2022-11-30 | — | — | EP | disclosed |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | UNITED THERAPEUTICS CORPORATION (US) | 2022-07-07 | — | — | US | disclosed |
| CN-114436978-A | Antifungal compound and application | 中国人民解放军海军军医大学 | 2022-05-06 | — | — | CN | disclosed |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | ABBVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | ABBOTT LABORATORIES | 2002-11-21 | — | — | US | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5861532-A | Solid-phase synthesis of N-alkyl amides | CHIRON CORPORATION (US) | 1999-01-19 | — | — | US | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| EP-0561882-B1 | HYDROXAMIC ACID DERIVATIVES WHICH INHIBIT LIPOXYGENASE | PFIZER (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0561882-A1 | HYDROXAMIC ACID DERIVATIVES WHICH INHIBIT LIPOXYGENASE. | PFIZER (US) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010469-A1 | HYDROXAMIC ACID DERIVATIVES WHICH INHIBIT LIPOXYGENASE | PFIZER INC. (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173665-A1 | Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | MAOA 1194/4885MAOB 1582/4885NPC1 4035/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | MAOA 1684/4885MAOB 1249/4885NPC1 496/4885 |
| US-20220213020-A1 | SYNTHESIS OF INTERMEDIATES FOR PRODUCING PROSTACYCLIN DERIVATIVES | PTGIS, PTGIR, PTGES | MAOA 1169/4885MAOB 1092/4885NPC1 1628/4885 |
| US-20030083359-A1 | Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors | P2RX3, P2RX1, P2RX2 | MAOA 866/4885MAOB 1422/4885NPC1 4215/4885 |
| US-20250282795-A1 | EGFR Inhibitors in cancer treatment | EGFR, ERBB2, ERBB4 | MAOA 1608/4885MAOB 2197/4885NPC1 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.